Quarterly paliperidone injection for patients with schizophrenia

Trevicta (paliperidone palmitate) is a 3-monthly sustained-release injection for the maintenance treatment of schizophrenia. It can be given once patients are clinically stable on monthly paliperidone palmitate injection (Xeplion).

The extended dosing interval of Trevicta may help to reduce the risk of relapse caused by poor adherence to treatment.

Further information
View Trevicta drug record
Manufacturer: Janssen-Cilag

Trevicta is administered by intramuscular injection into the deltoid or gluteal muscle, with dose adjustments when required within the range of 175mg to 525mg.

Similar to other antipsychotics, the most common adverse effects experienced by patients given the quarterly paliperidone palmitate injection included insomnia, extrapyramidal effects, weight change, hyperglycaemia, urinary tract infection, upper respiratory tract infection and headache.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Ranitidine in short supply after contamination fears prompt precautionary recall

Ranitidine in short supply after contamination fears prompt precautionary recall

GPs have reported shortages of ranitidine following...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Alzhok and ranitidine oral soln.
Use our...

Excessive steroid dosing highlighted in inflammatory bowel disease

Excessive steroid dosing highlighted in inflammatory bowel disease

Some patients with Crohn's disease or ulcerative colitis...